Check this out. I was messing around with ai ask to what it thought about the changes to the pre ispy trial here. I was trying to figure out the changes in trial sites.
One change is its now a phase 1/2 instead of 1b
PRE-I-SPYISPY Phase I/IbI/II Oncology Platform Program
"**Addition of Phase II and Minimal Residual Disease (MRD) Arms:**The text notes the addition of a Phase II component and specific sub-cohorts, such as Minimal Residual Disease Colorectal Cancer (MRD CRC). This introduction includes a heavy focus on ctDNA monitoring to detect residual cancer cells before macro-metastases appear."
Does anyone see the major change in this next first paragraph?
I didn't catch it a week back but ai caught it today
look hard
(It didn't paste correctly with crossed out verbiage.)
They removed the breast cancer focus and changed to "solid tumors"
I bet money Mayo is going to do both our breast cancer and pancreatic study for a couple reasons. And that most likely nobody, or almost nobody here cares lol
https://clinicaltrials.gov/study/NCT05868226?...tent-panel
"IPRE-SPYISPY Phase I/IbII (I-SPY-P1) is an open-label, multisite platform study with multiple ongoing drug regimen arms added by protocol amendment which is designed to evaluate single agents or combinations in a locally advanced, incurable, or metastatic treatment setting that may be relevant for ***breast cancer patients/ solid tumors*** and/or oligometastatic malignancy and/or a high risk of recurrence following prior treatment with the curative intent. The overall goal ofis moving promising drug regimens into a larger phase II (or III) trial and in general could feed the neoadjuvant breast I-SPY 2 SMART Design Trial (NCT01042379) and/or other oncology~~-based trials~~ solid tumor trial in a timely manner".
One change is its now a phase 1/2 instead of 1b
PRE-I-SPYISPY Phase I/IbI/II Oncology Platform Program
"**Addition of Phase II and Minimal Residual Disease (MRD) Arms:**The text notes the addition of a Phase II component and specific sub-cohorts, such as Minimal Residual Disease Colorectal Cancer (MRD CRC). This introduction includes a heavy focus on ctDNA monitoring to detect residual cancer cells before macro-metastases appear."
Does anyone see the major change in this next first paragraph?
I didn't catch it a week back but ai caught it today
look hard
(It didn't paste correctly with crossed out verbiage.)
They removed the breast cancer focus and changed to "solid tumors"
I bet money Mayo is going to do both our breast cancer and pancreatic study for a couple reasons. And that most likely nobody, or almost nobody here cares lol
https://clinicaltrials.gov/study/NCT05868226?...tent-panel
"IPRE-SPYISPY Phase I/IbII (I-SPY-P1) is an open-label, multisite platform study with multiple ongoing drug regimen arms added by protocol amendment which is designed to evaluate single agents or combinations in a locally advanced, incurable, or metastatic treatment setting that may be relevant for ***breast cancer patients/ solid tumors*** and/or oligometastatic malignancy and/or a high risk of recurrence following prior treatment with the curative intent. The overall goal ofis moving promising drug regimens into a larger phase II (or III) trial and in general could feed the neoadjuvant breast I-SPY 2 SMART Design Trial (NCT01042379) and/or other oncology~~-based trials~~ solid tumor trial in a timely manner".
2
